A R T I C L E S
Kaluzna et al.
from competing enzymes. Since each fusion protein is produced
from the corresponding cloned gene, relationships between
genotype and phenotype are established directly. In this report,
we describe the application of the methodology to the systematic
study of reductases produced by baker’s yeast (Saccharomyces
Scheme 1
11
cereVisiae).
Since the seminal studies by Neuberg,12 baker’s yeast cells
have been the most popular biocatalyst for asymmetric ketone
reductions (for recent reviews, see 13-15). The substrate
acceptance of this organism is very broad, and using com-
mercially available whole cells is both experimentally simple
and inexpensive. Unfortunately, such reductions are often
bedeviled by poor stereoselectivities, which can be traced to
the presence of multiple enzymes with divergent enantio- and
diastereomeric preferences. Notable efforts to overcome this
problem have included adjusting the substrate concentration and
16
structure (to favor acceptance by a subset of yeast reductases),
including additives to poison one or more competing en-
7,17,18
19,20
zymes,
and genetic knockout/overexpression approaches.
In practice, these strategies have often proven only partially
successful. The reason for these difficulties became clear from
our analysis of the complete yeast genome, which revealed that
the protein products of ca. fifty open reading frames might
catalyze ketone reductions.21 Clearly, it would be very difficult
to devise a set of selective inhibitors for such a large collection
of reductases. Likewise, our earlier strategy based on creating
targeted gene knockouts in hopes of improving the stereose-
lectivities of yeast reductions was also not viable, given the
number of yeast genes that would have to be inactivated
simultaneously.20 By contrast, screening individual, cloned
fusion proteins not only allows their substrate- and stereose-
lectivities to be determined cleanly, but also provides a rapid
entry into heterologous overexpression systems (such as engi-
neered Escherichia coli cells) that often offer both high
volumetric productivities and freedom from competing reduc-
of these candidates were eliminated, either because they were
known or suspected to have narrow substrate specificities (zinc-
containing yeast alcohol dehydrogenases, for example) or their
sequence similarities to bona fide reductases was low. The
winnowing process left 22 open reading frames that included
23
2
4
25
members of the aldose reductase, short-chain, medium-
2
6
chain, and D-hydroxyacid dehydrogenase superfamilies. We
considered these the most promising candidates for discovering
synthetically useful biocatalysts.
The original method for preparing the yeast GST-fusion
1
0
proteins relied on overexpression in baker’s yeast. While this
approach most closely mimics the native environment for these
proteins, the choice of host cell limited protein overexpression
to modest levels. Preliminary studies showed that the level of
GST-fusion protein production in yeast cells was not sufficient
to allow their activities toward nonnatural substrates to be
assessed reliably. We therefore used standard molecular biology
techniques to create E. coli overexpression plasmids for each
of the twenty-two GST fusion proteins of interest for this study.
These constructs retained the identical protein coding regions
but utilized the strong T7 promoter for bacterial overexpression.
The fusion proteins were purified by affinity chromatography
on glutathione-agarose and they appeared to retain their catalytic
activities for at least a year when stored at -20 °C in 50%
2
2
tases.
Results and Discussion
This study explored the properties of twenty two S. cereVisiae
reductases. This group was selected from our earlier analysis
of the yeast genome, which revealed that 49 open reading frames
encoded known or putative reductases.21 Approximately half
(
11) Kaluzna, I.; Andrew, A. A.; Bonilla, M.; Martzen, M. R.; Stewart, J. D. J.
Mol. Catal. B: Enzymatic 2002, 17, 101-105.
(
12) Neuberg, C.; F., N. F. Biochem. Z. 1914, 62, 482-488.
13) Sybesma, W. F. H.; Straathof, A. J. J.; Jongejan, J. A.; Pronk, J. T.; Heignen,
J. J. Biocatal. Biotrans. 1998, 16, 95-134.
27
glycerol. This allowed us to keep the library of yeast reductases
(
on hand for rapid screening.
(
14) Stewart, J. D. Curr. Opin. Drug DiscoVery DeVelopment 1998, 1, 278-
A representative panel of â- and R-keto esters was selected
to profile the substrate- and enantioselectivities of the isolated
yeast proteins (Scheme 1). These compounds were selected so
that data from homologous structures might reveal useful trends
that could be applied to guide future synthetic applications. In
addition, several of the alcohol products from these reductions
have been used as chiral building blocks. For example, Corr eˆ a
and co-workers have employed (R)-3d in their synthesis of (S)-
2
89.
(
15) Santaniello, E.; Ferraboschi, P.; Manzocchi, A. In Enzymes in Action. Green
Solutions for Chemical Problems; Zwanenburg, B., Mikolajczyk, M. and
Kielbasinski, P., Eds.; Kluwer Academic Publishers: Dordrecht, 2000, pp
9
5-115.
(
16) Sih, C. J.; Zhou, B.-N.; Gopalin, A. S.; Shieh, W.-R.; VanMiddlesworth,
F. Sel., Goal. Synth. Effic., Proc. Workshop Conf. Hoechst. 14th 1983, 184,
2
51-261.
(
(
(
(
(
17) Nakamura, K.; Inoue, K.; Oshio, K.; Oka, S.; Ohno, A. Chem. Lett. 1987,
79-682.
18) Nakamura, K.; Kawai, Y.; Oka, S.; Ohno, A. Bull. Chem. Soc. Jpn. 1989,
2, 875-879.
19) Rodriguez, S.; Kayser, M. M.; Stewart, J. D. Org. Lett. 1999, 1, 1153-
155.
20) Rodriguez, S.; Kayser, M. M.; Stewart, J. D. J. Am. Chem. Soc. 2001,
6
6
1
(23) Leskovac, V.; Trivic, S.; Pericin, D. FEMS Yeast Res. 2002, 2, 481-494.
(24) Jez, J. M.; Penning, T. M. Chemico-Biol. Interactions 2001, 130-132, 499-
525.
(25) Krozowski, Z. J. Steroid Biochem. Mol. Biol. 1994, 51, 125-130.
(26) Persson, B.; Zigler, J. S.; J o¨ rnvall, H. Eur. J. Biochem. 1994, 226, 15-22.
(27) Four of the overexpression strains yielded the fusion proteins as insoluble
inclusion bodies, and these were eliminated from further study (YOR388c,
YMR318c, YCR105w, and YJR159w).
1
23, 1547-1555.
21) Stewart, J. D.; Rodriguez, S.; Kayser, M. M. In Enzyme Technologies for
Pharmaceutical and Biotechnological Applications; Kirst, H. A., Yeh, W.-
K. and Zmijewski, M. J., Eds.; Marcel Dekker: New York, 2001, pp 175-
2
08.
(22) Walton, A. Z.; Stewart, J. D. Biotechnol. Prog. 2004, 20, 403-411.
1
2828 J. AM. CHEM. SOC. VOL. 126, NO. 40, 2004
9